Hepatitis B: Our Current Understanding

2022 Special Edition, Issue 1

Hepatitis B: Our Current Understanding

In this issue:

Hepatitis B. Unlike Hep C, it’s not curable — yet. But as the research continues and the knowledge base continues to grow, the cure gets closer and closer. But what can be done to benefit patients now? And what can clinicians and patients expect in the near future? That’s the focus of this Special HBV Edition of eViralHepatitis Review.

This first part presents an evidence-based multimedia Expert Commentary by eViralHepatitis Review Program Director Dr. Mark Sulkowski — Professor of Medicine at Johns Hopkins and Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center — and is expanded by brief audio discussions with three top viral hepatitis experts. The second part of the program, available without charge at eviralhepatitisreview.org, is a full podcast providing more in-depth discussions with these experts.

Learning objectives:

Discuss the current AASLD guidance for recommended medications for the treatment of patients with chronic HBV infection.
Explain considerations for patients whose HBV disease is characterized as not meeting the criteria for treatment.
Describe the management of hepatitis B in persons coinfected with HIV, Hepatitis C, and/or Hepatitis D.

Authors:

Mark S. Sulkowski, MD

Professor of Medicine
Division of Infectious Diseases
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology and Hepatology
Johns Hopkins School of Medicine
Baltimore, Maryland

Debika Bhattacharya, MD

Associate Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

Norah Terrault, MD, MPH, FAASLD

Professor of Medicine, Chief, Division of GI and Liver
Neil Kaplowitz Chair in Liver Diseases
Keck School of Medicine
University of Southern California
Los Angeles, California

Jordan Feld, MD, MPH

Professor of Medicine
Interim Director, Toronto Centre for Liver Disease
University Health Network
University of Toronto
Toronto, Canada

Guest Faculty Disclosures

Dr. Feld has indicated that he has served as an advisor for AbbVie, Gilead Sciences, Johnson and Johnson, Enanta, Eiger, Arbutus, Antios, Vir, and GlaxoSmithKline. He has also received grant or research support from AbbVie, Gilead Sciences, Inc., Eiger, Wako/Fujifilm, Johnson and Johnson, GlaxoSmithKline, and Roche.  

Dr. Terrault has indicated that she has received consulting fees from Moderna. She has received grant or research support from Gilead Sciences, Inc., Roche, GlaxoSmithKline, Helio Health, and DURECT. She has served on membership or advisory committees or review panels for AASLD and AASLD Foundation, and received honoraria from CCO Hepatitis.

Dr. Bhattacharya has indicated that she has received grant or research support from Gilead Sciences, Inc. and Regeneron.

Unlabeled/Unapproved Uses

The authors have indicated that there will be references to the unlabeled/unapproved uses of bulevirtide. 

Program Directors:

Mark S. Sulkowski, MD

Lee Gilman, MSN-AGNP, CRNP

Nurse Practitioner, Viral Hepatitis Center
The John G. Bartlett Specialty Practice, Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Guest Faculty Disclosures:

Dr. Bhattacharya has indicated that she has received grant or research support from Gilead Sciences, Inc. and Regeneron.

Unlabeled/Unapproved Uses:

The authors have indicated that there will be references to the unlabeled/unapproved uses of bulevirtide. 

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: October 20, 2022
Expiration date: October 19, 2024

Start Issue